Abbott Laboratories (NYSE:ABT) Q4 2024 Earnings Conference Call January 22, 2025 9:30 AM ET
Company Participants
Mike Comilla – Vice President, Investor Relations
Robert Ford – Chairman & Chief Executive Officer
Phil Boudreau – Executive Vice President, Finance & Chief Financial Officer
Conference Call Participants
Robbie Marcus – JPMorgan
Larry Biegelsen – Wells Fargo
Travis Steed – BofA Securities
Vijay Kumar – Evercore ISI
Josh Jennings – TD Cowen
David Roman – Goldman Sachs
Joanne Wuensch – Citi
Danielle Antalffy – UBS
Matt Miksic – Barclays
Operator
Good morning and thank you for standing by. Welcome to Abbott’s Fourth Quarter 2024 Earnings Conference Call. All participants will be able to listen only until the question-and-answer portion of this call. [Operator Instructions] This call is being recorded by Abbott. With the exception of any participant’s questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott’s express written permission.
I would now like to introduce Mr. Mike Comilla, Vice President, Investor Relations.
Mike Comilla
Good morning and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer; and Phil Boudreau, Executive Vice President, Finance and Chief Financial Officer. Robert and Phil will provide opening remarks. Following their comments, we’ll take your questions.
Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2025. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological, and other factors that may affect Abbott’s operations are discussed in Item 1A, Risk Factors, to our annual report on Form 10-K for the year-ended December 31, 2023. Abbott undertakes
#Abbott #Laboratories #ABT #Earnings #Call #Transcript